» Articles » PMID: 8306954

Paroxysmal Nocturnal Haemoglobinuria (PNH) is Caused by Somatic Mutations in the PIG-A Gene

Overview
Journal EMBO J
Date 1994 Jan 1
PMID 8306954
Citations 84
Authors
Affiliations
Soon will be listed here.
Abstract

Paroxysmal nocturnal haemoglobinuria (PNH), an acquired clonal blood disorder, is caused by the absence of glycosyl phosphatidylinositol (GPI)-anchored surface proteins due to a defect in a specific step of GPI-anchor synthesis. The cDNA of the X-linked gene, PIG-A, which encodes a protein required for this step has recently been isolated. We have carried out a molecular and functional analysis of the PIG-A gene in four cell lines deficient in GPI-linked proteins, obtained by Epstein-Barr virus (EBV) transformation of affected B-lymphocytes from PNH patients. In all four cell lines transfection with PIG-A cDNA restored normal expression of GPI-linked proteins. In three of the four cell lines the primary lesion is a frameshift mutation. In two of these there is a reduction in the amount of full-length mRNA. The fourth cell line contains a missense mutation in PIG-A. In each case the mutation was present in the affected granulocytes from peripheral blood of the patients, but not in normal sister cell lines from the same patient. These data prove that PNH is caused in most patients by a single mutation in the PIG-A gene. The nature of the mutation can vary and most likely occurs on the active X-chromosome in an early haematopoietic stem cell.

Citing Articles

Somatic mutations in Brazilian patients with paroxysmal nocturnal hemoglobinuria: a comprehensive analysis.

Eiko Yamakawa P, Perez Gomes C, Ribeiro Mendes A, Cesar Justino de Oliveira C, Porto Freitas F, Bettoni F Front Med (Lausanne). 2025; 12:1472186.

PMID: 40066167 PMC: 11891177. DOI: 10.3389/fmed.2025.1472186.


Beyond Recycling Antibodies: Crovalimab's Molecular Design Enables Four-Weekly Subcutaneous Injections for PNH Treatment.

Sampei Z, Haraya K, Gan S, Muraoka M, Hayasaka A, Fukuzawa T Int J Mol Sci. 2024; 25(21).

PMID: 39519232 PMC: 11546984. DOI: 10.3390/ijms252111679.


Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors.

Hillmen P, Horneff R, Yeh M, Kolev M, Deschatelets P Int J Mol Sci. 2024; 25(17).

PMID: 39273426 PMC: 11395449. DOI: 10.3390/ijms25179477.


Germline variants in acquired aplastic anemia: current knowledge and future perspectives.

Wang P, Jiang W, Lai T, Liu Q, Shen Y, Ye B Haematologica. 2024; 109(9):2778-2789.

PMID: 38988263 PMC: 11367197. DOI: 10.3324/haematol.2023.284312.


Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan.

Mulherin B, Yeh M, Al-Adhami M, Dingli D Drugs R D. 2024; 24(2):169-177.

PMID: 38727860 PMC: 11315842. DOI: 10.1007/s40268-024-00463-9.


References
1.
Urlaub G, Mitchell P, Ciudad C, Chasin L . Nonsense mutations in the dihydrofolate reductase gene affect RNA processing. Mol Cell Biol. 1989; 9(7):2868-80. PMC: 362753. DOI: 10.1128/mcb.9.7.2868-2880.1989. View

2.
Smith C, Patton J, Nadal-Ginard B . Alternative splicing in the control of gene expression. Annu Rev Genet. 1989; 23:527-77. DOI: 10.1146/annurev.ge.23.120189.002523. View

3.
Hillmen P, Bessler M, Crawford D, Luzzatto L . Production and characterization of lymphoblastoid cell lines with the paroxysmal nocturnal hemoglobinuria phenotype. Blood. 1993; 81(1):193-9. View

4.
De Sandre G, Ghiotto G, Mastella G . [Erythrocytic acetylcholinesterase. II. Relations to hemolytic diseases]. Acta Med Patav. 1956; 16(3):310-35. View

5.
Takahashi M, Takeda J, Hirose S, HYMAN R, Inoue N, Miyata T . Deficient biosynthesis of N-acetylglucosaminyl-phosphatidylinositol, the first intermediate of glycosyl phosphatidylinositol anchor biosynthesis, in cell lines established from patients with paroxysmal nocturnal hemoglobinuria. J Exp Med. 1993; 177(2):517-21. PMC: 2190897. DOI: 10.1084/jem.177.2.517. View